Medtronic recently announced a series of senior management changes, including the appointment of Linnea Burman as the new Senior Vice President and President of the Neurovascular business unit, succeeding Dan Volz, who will transition to the role of Senior Vice President of Global Commercial Transformation. Additionally, Emily Elswick, former Vice President of the Chief Executive Office, has been appointed as the President of the Pelvic Health business and will continue as a member of the Neuroscience leadership team.
Linnea Burman previously served as Vice President and General Manager of Support Technologies at Medtronic's Cranial and Spinal Technologies (CST) division before joining the Neurovascular business. She brings over 20 years of experience in managing global teams. Throughout her career, she has played a key role in advancing the post-stroke spasticity market and has built strong relationships with renowned stroke neurologists and patient advocacy organizations. In her new role, Burman will oversee product portfolio strategy, product development, and commercial execution within the Stroke Therapies division, reporting to Brett Wall, Executive Vice President and President of Medtronic’s Neuroscience Portfolio.
"Linnea is a strategic and visionary leader who always adheres to the customer-first philosophy while building and developing high-performance teams," Wall said. "Her outstanding track record, deep knowledge of the medical technology industry, and experience in stroke treatment demonstrate her business acumen and underscore her commitment to making a significant impact on patient outcomes. I am fully confident that under her leadership, the neurovascular business will continue to thrive."
In addition to her business responsibilities, Burman also leads inclusive and supportive professional networks. She serves as the Executive Chair of the ASPIRE network, which supports the growth, development, and success of Medtronic’s female field employees. She is also involved in the Medtronic Women’s Network (MWN). During her tenure in the CST division, she founded ET Enablers, a global employee group dedicated to enhancing two-way communication and collaboration.Medtronic recently announced that Emily Elswick has been appointed as the new President of the Pelvic Health business and has become a key member of the Neuroscience leadership team. Elswick previously served as Vice President of the CEO's Office at Medtronic, leading the execution of the company’s strategic initiatives. Brett Wall, Executive Vice President of Medtronic’s Neuroscience division, spoke highly of Elswick, describing her as a bold, goal-oriented leader with a strong business background who stands out in fiercely competitive markets.
Before overseeing the Pelvic Health business, Elswick managed Medtronic's Lung Health and Visualization division as Vice President and General Manager, leading global teams in the development of minimally invasive diagnostic and therapeutic technologies. She not only championed inclusion, diversity, and equity initiatives internally but also played a leadership role in the Medtronic Women’s Network (MWN), making significant contributions to the company’s culture and community building.
Continuously Growing Neuro Products Line
Sustained Growth Driven by Innovation: Medtronic’s Neuroscience DivisionMedtronic's neuroscience division is committed to covering a wide range of therapeutic areas, including neuromodulation, brain, and spine surgery. The division focuses on the development of innovative products, launching the FDA-approved Percept™ RC neurostimulator and BrainSense™ technology, which have received enthusiastic market responses. Through strategic acquisitions and collaborations, Medtronic has further solidified its leadership in the neuroscience field, particularly in spinal technology, significantly strengthening its capabilities following the acquisition of Medicrea.
According to the fiscal year 2024 fourth quarter and full-year financial report, Medtronic's neuroscience product line continues to maintain its growth momentum, particularly achieving significant progress in the spine and neuromodulation fields. The financial report shows that Medtronic's revenue for the fiscal year 2024 reached$9.406 billion，Year-on-year growth of 5.0%, with an organic growth rate of 5.2%The CST division achieved high single-digit growth, while Specialty Therapies and Neuromodulation reached mid and low single-digit growth respectively, all driven by organic growth.Revenue in the fourth quarter was $2.545 billion, increasing by 5.6%, with organic growth of 6.5%, among which CST performed particularly outstandingly.- CST's Performance in the Fourth Quarter Affected byContinued Adoption of the AiBLE™ EcosystemThe mid-teens growth in Neurosurgery was driven by strong capital equipment sales, high single-digit growth in Biologics, and mid-single-digit growth in Core Spine.
- The performance of the Professional Therapies segment in the fourth quarter was driven by high single-digit growth in ENT, strong momentum in capital equipment and disposables, and robust sales of local drug delivery sinus implants; neurovascular declined slightly due to volume-based procurement tenders in China offsetting the strength in flow diversion products; and continued adoption.InterStim X™ SystemPelvic health grew by mid-single digits.
- With the adoptionBrainSense™ TechnologyThePercept™ RC NeurostimulatorThe launch of brain modulation in neuroregulation achieved low double-digit growth in the fourth quarter; pain therapies grew by a mid-single-digit rate, including low double-digit growth in targeted drug delivery and low single-digit growth in Pain Stim.
- On the last day of the fourth quarter, received approval from the U.S. Food and Drug Administration forInceptiv™ Closed-Loop Spinal Cord StimulatorApproval;OsteoCool™ 2.0 Bone Tumor Ablation SystemReceived FDA approval in the fourth quarter and is planned for widespread availability later this calendar year.
Medtronic Places Equal Importance on Its Neurovascular Business: Newly Appointed President of Neurovascular Business, Linnea Burman, to Lead the Team in Achieving More Breakthroughs in Innovation and Market Expansion. The Company Plans to Launch Neurovascular Products in More Countries and Regions Through Localization Strategies and Partnerships. In the Future, Medtronic May Offer a More Comprehensive Stroke Treatment and Prevention Solution, Including Full-Process Management Before, During, and After Surgery, to Improve Patients' Overall Treatment Outcomes and Quality of Life.
View the Neurology Product Market with a Full Field of Vision
The global neurology products market is currently experiencing strong growth and is projected to continue expanding in the coming years. The market size in 2021 was approximately$124 billion, and is expected to reach by 2028205 billionDollar，The average annual growth rate is 7.4%.The main factors driving this growth include the high incidence of neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease) and mental health issues (such as anxiety disorders, epilepsy), as well as the introduction of new drugs and treatment options in these areas.
In the competition within the field of neuroscience, Medtronic is undoubtedly a heavyweight player, with a strong and technologically advanced product line in neuromodulation and neurosurgical devices. For instance,Percept™ RC Neural StimulationStimulatorIt is a representative of its innovative products, which has received FDA approval and achieved remarkable success in the market. In addition, Medtronic has also launchedBrainSense™ Technology, further consolidating its position in this field.
Boston ScientificAlso occupies a place in the neuroscience market, especially inSacral Neuromodulation Therapy FieldThrough acquisitions and continuous innovation, Boston Scientific has consolidated its market share in niche markets. Other major competitors such asJohnson & JohnsonAndStrykerAlso occupies an important share in the neurology product market.Looking to the future, Medtronic is committed to expanding its product portfolio in the neuroscience field and addressing unmet medical needs through innovative technologies and treatment solutions. The company anticipates that its neuroscience business line will continue its strong growth momentum with the launch of new products and further market expansion. Additionally, Medtronic plans to strengthen its leadership position in the neuroscience sector by enhancing global strategies and investments.
▲ Source of the article: Medical Device Innovation Network▲Please indicate the source above when reprintingDisclaimer: This article is for informational purposes only and serves as a reference. It does not constitute any advice on investment or treatment; please evaluate carefully. If the content, copyright, or other issues of the article are involved, to protect the rights and interests of both parties, please contact us and we will handle it immediately. If this article is reprinted by any platform, the platform shall be responsible for the article itself; the Medical Device Innovation Network is not responsible for any secondary dissemination caused by the reprint.
